PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
|Articles|December 15, 2004
A First for Parexel
The first multipurpose cGMP contract manufacturing facility in South Korea, the Korea Biotechnology Commercialization Center (KBCC), will be validated by Parexel International.
Advertisement
The first multipurpose cGMP contract manufacturing facility in South Korea, the Korea Biotechnology Commercialization Center (KBCC), will be validated by Parexel International. As part of an agreement with the Korea Institute of Industrial Technology (KITECH), Parexel Consulting will provide KBCC with a team of on-site validation engineering consultants and regulatory experts to train KBCC personnel, and validate the manufacturing facility, its utilities and process equipment.
"Parexel Consulting's experts will collaborate with KITECH management to position the KBCC manufacturing facility to meet or exceed current FDA and cGMP standards, thus providing a regulatory compliant foundation for future therapies to achieve regulatory approval," said Kurt A. Brykman, president of Parexel Consulting.
Advertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
4
Lessons For AI Governance in Quality Systems
5